

Amendments to the Claims

The following listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-105. (Canceled)

106. (Currently amended) A method for transporting a non-steroidal anti-inflammatory drug through intact human or animal skin or mucous membranes, comprising administering to the skin or a mucous membrane of a human or an animal a vesicular composition comprising:

- (a) a vesicle consisting essentially of:
 - i) one or more phosphatidyl cholines;
 - ii) a salt of one or more non-steroidal anti-inflammatory drugs; and
 - iii) one or more antioxidants ~~of phenol, cresol or benzyl alcohol~~,wherein an aqueous medium is contained within the vesicle ~~and wherein said vesicle has a size of 50 to 500 nm~~; and
- (b) the aqueous medium,

wherein the vesicle is capable of penetrating through a permeability barrier having at least one constriction, and the vesicle is larger than the constriction by more than a factor of 2 and less than a factor of 4.

107. (Previously Presented) The method of claim 106, wherein the aqueous medium is a buffer.

108. (Previously Presented) The method of claim 107, wherein the buffer has a pH of 3 to 12.

109. (Previously Presented) The method of claim 108, wherein the buffer has a pH of 5 to 9.

110. (Previously Presented) The method of claim 109, wherein the buffer has a pH of 6 to 8.

111. (Canceled)

112. (Previously presented) The method of claim 106, wherein at least one of the one or more phosphatidyl cholines is a natural phosphatidyl choline.

113. (Previously presented) The method of claim 112, wherein at least one of the one or more phosphatidyl cholines is from egg, soybean, coconut, olive, saffron, sunflower, linseed, whale fat, primrose, or primula.

114. (Previously presented) The method of claim 106, wherein at least one of the one or more phosphatidyl cholines is a synthetic phosphatidyl choline.

115. (Previously presented) The method of claim 106, wherein at least one of the one or more non-steroidal anti-inflammatory drugs is diclofenac or ibuprofen.

116. (Canceled)

117. (Canceled)

118. (Currently amended) The method of claim ~~116~~ 106, wherein the antioxidant is probucol, tocopherol, BHT, ascorbic acid, or desferroxamine.

119. (Canceled)

120. (Previously Presented) The method of claim 106, wherein up to 50 mg of the vesicular composition are administered per cm² of skin surface.

121. (Previously presented) The method of claim 106, wherein the salt is a lithium, sodium, potassium, cesium, rubidium, ammonium, monomethyl, dimethyl, trimethylammonium or ethylammonium salt.

122. (Previously presented) The method of claim 106, wherein the vesicle has a size of 75 to 400 nm.

123. (Previously presented) The method of claim 122, wherein the vesicle has a size of 100 to 200 nm.

124. (New) A method for transporting a non-steroidal anti-inflammatory drug through intact human or animal skin or mucous membranes, comprising administering to the skin or a mucous membrane of a human or an animal a vesicular composition comprising:

- (a) a vesicle consisting essentially of:
 - i) one or more phosphatidyl cholines;
 - ii) a salt of one or more non-steroidal anti-inflammatory drugs;
 - iii) one or more antioxidants; and
 - iv) one or more consistency modifiers and/or one or more stabilizers,wherein an aqueous medium is contained within the vesicle; and
- (b) the aqueous medium,

wherein the vesicle is capable of penetrating through a permeability barrier having at least one constriction, and the vesicle is larger than the constriction by more than a factor of 2 and less than a factor of 4.

125. (New) The method of claim 124, wherein the aqueous medium is a buffer.

126. (New) The method of claim 125, wherein the buffer has a pH of 3 to 12.

127. (New) The method of claim 125, wherein the buffer has a pH of 5 to 9.

128. (New) The method of claim 125, wherein the buffer has a pH of 6 to 8.
129. (New) The method of claim 124, wherein at least one of the one or more phosphatidyl cholines is a natural phosphatidyl choline.
130. (New) The method of claim 124, wherein at least one of the one or more phosphatidyl cholines is from egg, soybean, coconut, olive, saffron, sunflower, linseed, whale fat, primrose, or primula.
131. (New) The method of claim 124, wherein at least one of the one or more phosphatidyl cholines is a synthetic phosphatidyl choline.
132. (New) The method of claim 124, wherein at least one of the one or more non-steroidal anti-inflammatory drugs is diclofenac or ibuprofen.
133. (New) The method of claim 124, wherein the consistency modifier is a hydrogel.
134. (New) The method of claim 124, wherein the stabilizer is phenol, cresol, or benzyl alcohol.
135. (New) The method of claim 124, wherein up to 50 mg of the vesicular composition are administered per cm² of skin surface.
136. (New) The method of claim 124, wherein the salt is a lithium, sodium, potassium, cesium, rubidium, ammonium, monomethyl, dimethyl, trimethylammonium or ethylammonium salt.
137. (New) The method of claim 124, wherein the vesicle has a size of 75 to 400 nm.

Appl. No. 09/284,683
Amdt. dated August 18, 2008
Reply to Office Action of April 2, 2008

138. (New) The method of claim 124, wherein the vesicle has a size of 100 to 200 nm.